Integrating Immunotherapy in Resectable NSCLC

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJW865. CME/MOC/AAPA/IPCE credit will be available until November 8, 2025.
Integrating Immunotherapy in Resectable NSCLC: How to Modify Treatment Trajectories and Reorganize Multidisciplinary Care Pathways
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported through independent educational grants from AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc, Rahway, NJ, USA.
Disclosure information is available at the beginning of the video presentation.